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REVIEW
Abstract: New growth in the vascular network is important since the proliferation, as well as
metastatic spread, of cancer cells depends on an adequate supply of oxygen and nutrients and
the removal of waste products. New blood and lymphatic vessels form through processes
called angiogenesis and lymphangiogenesis, respectively. Angiogenesis is regulated by both
activator and inhibitor molecules. More than a dozen different proteins have been identified
as angiogenic activators and inhibitors. Levels of expression of angiogenic factors reflect the
aggressiveness of tumor cells. The discovery of angiogenic inhibitors should help to reduce
both morbidity and mortality from carcinomas. Thousands of patients have received
antiangiogenic therapy to date. Despite their theoretical efficacy, antiangiogeic treatments
have not proved beneficial in terms of long-term survival. There is an urgent need for a new
comprehensive treatment strategy combining antiangiogenic agents with conventional
cytoreductive treatments in the control of cancer.
Keywords: angiogenesis, immunohistochemistry, prognosis
Introduction
Cancer has the ability to spread to adjacent or distant organs, which makes it life
threatening. Tumor cells can penetrate blood or lymphatic vessels, circulate through
the intravascular stream, and then proliferate at another site: metastasis (Folkman
1971). For the metastatic spread of cancer tissue, growth of the vascular network is
important. The processes whereby new blood and lymphatic vessels form are called
angiogenesis and lymphangiogenesis, respectively. Both have an essential role in
the formation of a new vascular network to supply nutrients, oxygen and immune
cells, and also to remove waste products (Folkman 1971). Angiogenic and
lymphangiogenic factors are increasingly receiving attention, especially in the field
of neoplastic vascularization.
Angiogenesis in cancer
Tumor growth and metastasis depend on angiogenesis and lymphangiogenesis
triggered by chemical signals from tumor cells in a phase of rapid growth (Folkman
1971). In a previous study, Muthukkaruppan and colleagues (1982) compared the
behavior of cancer cells infused into different regions of the same organ. One region
was the iris with blood circulation; another was the anterior chamber without
circulation. The cancer cells without blood circulation grew to 1–2 mm3 in diameter
and then stopped, but grew beyond 2 mm
3 when placed in an area where angiogenesis
was possible. In the absence of vascular support, tumors may become necrotic or
even apoptotic (Holmgren et al 1995; Parangi et al 1996). Therefore, angiogenesis is
an important factor in the progression of cancer. Neovascularization, including tumor
angiogenesis, is basically a four-step process. First, the basement membrane in tissues
is injured locally. There is immediate destruction and hypoxia. Second, endothelial
cells activated by angiogenic factors migrate. Third, endothelial cells proliferate and
stabilize. Fourth, angiogenic factors continue to influence the angiogenic process.
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Vascular endothelial cells divide only about every 1000 days
on average (Denekamp 1993). Angiogenesis is stimulated
when tumor tissues require nutrients and oxygen.
Angiogenesis is regulated by both activator and inhibitor
molecules. However, up-regulation of the activity of
angiogenic factors is itself not sufficient for angiogenesis
of the neoplasm. Negative regulators or inhibitors of vessel
growth need to also be down-regulated (Figure 1) (Dameron
et al 1994).
Endogenous angiogenic factors
More than a dozen different proteins have been identified
as angiogenic activators, including vascular endothelial
growth factor (VEGF), basic fibroblast growth factor
(bFGF), angiogenin, transforming growth factor (TGF)-α,
TGF-β, tumor necrosis factor (TNF)-α, platelet-derived
endothelial growth factor, granulocyte colony-stimulating
factor, placental growth factor, interleukin-8, hepatocyte
growth factor, and epidermal growth factor (Table 1). The
VEGF family and their receptors (VEGFR) are receiving
increasingly more attention in the field of neoplastic
vascularization. VEGF is a powerful angiogenic agent in
neoplastic tissues, as well as in normal tissues. Under the
influence of certain cytokines and other growth factors, the
VEGF family appears in cancerous tissue and the adjacent
stroma, and plays an important role in neovascularization
(Folkman 1990, 1995a, 1995b). Some angiogenic
phenotypes can be triggered by hypoxia resulting from the
increasing distance between the growing tumor cells and
the capillaries or from the inefficiency of new vessels.
Hypoxia induces the expression of VEGF and its receptor
via hypoxia-inducible factor-1α (HIF-1α) (Bottaro and
Liotta 2003). Tumor cells feed on the new blood vessels by
producing VEGF and then secreting it into the surrounding
tissue. When the tumor cells encounter endothelial cells,
they bind to receptors on the outer surface of the endothelial
cell. The binding of VEGF to its receptor activates relay
proteins that transmit a signal into the nucleus of the
endothelial cell. The nuclear signal prompts a group of genes
to make products needed for new endothelial cell growth.
Endothelial cells activated by VEGF produce matrix
metalloproteinases (MMPs). The MMPs break down the
extracellular matrix which fills the spaces between cells and
is made of protein and polysaccharides. This matrix permits
the migration of endothelial cells. The endothelial cells begin
to divide as they migrate into the surrounding tissues. Soon
they organize into hollow tubes that evolve gradually into a
mature network of blood vessels with the help of an adhesion
factor, such as integrin α or β (Mizejewski 1999; Nelson et
al 2000). Newly formed blood vessels need to stabilize or
mature. Angiotensin-1, -2, and their receptor Tie-2 can
stabilize and govern vascular growth (Suri et al 1996;
Maisonpierre et al 1997; Tournaire et al 2004).
Among the VEGF family, VEGF-A, VEGF-B, VEGF-
C and VEGF-E acting on their respective receptors cause
proliferation of blood vessels, while VEGF-C and VEGF-
D are involved in lymphangiogenesis (Neufeld et al 1999;
Mandriota et al 2001; Rafii and Skobe 2003). Vascular
endothelial growth factor-A is also known as VEGF/vascular
permeability factor (VPF) (Leung et al 1989). The human
VEGF-A gene has been mapped to 6q21.3 (Vincenti et al
1996). Vascular endothelial growth factor-A is a heparin-
binding glycoprotein that occurs in at least six molecular
isoforms, which consist of 121, 145, 165, 183, 189, and
206 amino acids and are the result of alternative splicing of
the mRNA (Ferrara et al 1992; Ferrara 1996; Stalmans et al
2002). VEGF-A is a potent and very specific mitogen for
vascular endothelial cells and stimulates the full cascade of
events required for angiogenesis (Leung et al 1989; Conn
et al 1990), and is overexpressed in a variety of tumors
(Dvorak 2002). VEGF-B exists as two protein isoforms,
VEGF-B167 and VEGF-B186, resulting from different
Figure 1 Angiogenesis is regulated by a balance between activators and inhibitors (a). When tumor tissues require fuel (nutrients and oxygen), angiogenesis is
stimulated. However, up-regulation of by the activity of angiogenic activators alone is not sufficient for angiogenesis of the neoplasm. Negative regulators or inhibitors
of vessel growth need also to be down-regulated (b).Vascular Health and Risk Management 2006:2(3) 215
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spliced mRNA and binds specifically to VEGFR-1.
However, VEGF-B forms a heterodimer with VEGF-A
(Olofsson et al 1996), which may alter its interaction with
its biological receptors and modify its normal physiological
effects. While VEGF-B is widely expressed in heart, skeletal
muscle, and vascular cells (Olofsson et al 1996; Yonekura
et al 1999), its biological function remains unclear. It has
also been reported that VEGF-B levels increase both
throughout development and after birth, closely correlating
with the progression of cardiac angiogenesis (Bellomo et al
2000). VEGF-C has a mature form that consists of a VEGF
homology domain, which contains receptor-binding sites
and is 30% identical in amino-acid sequence of VEGF165
(Joukov et al 1998). Unlike VEGF-A, the expression of
VEGF-C does not appear to be regulated by hypoxia
(Enholm et al 1997). The expression of VEGF-C appears to
be restricted to early development and certain pathological
settings such as tumor angiogenesis and lymphangiogenesis
(Peeper 2001). VEGF-D is known as c-FOS-induced growth
factor (FIGF), and the mature form has 61% identical amino-
acid sequence with VEGF-C, and both of these growth
factors bind to the same receptors on human endothelial
cells, namely VEGFR-2 and -3 (Orlandini et al 1996; Achen
et al 1998; Baldwin et al 2001). VEGF-C and VEGF-D bind
and activate VEGFR-3, regulating lymphangiogenesis as
well as angiogenesis in the mid-stages of embryogenesis
(Migdal et al 1998; Soker et al 1998). VEGF-E is encoded
by the parapoxvirus or Orf virus (Lyttle et al 1994). The
interaction of VEGF-E with its receptor seems to promote
endothelial cell growth (Ogawa et al 1998). There is a
significant overlap between the binding pocket of VEGF-A
and VEGF-E on VEGFR-2 which may suggest alliance of
the two molecules in final response or alternatively an
antagonistic relationship between these two factors (Kiba
et al 2003).
Inhibitors of angiogenesis
Up-regulation of the activity of angiogenic factors is in itself
not enough to initiate blood vessel growth, and the functions
of negative regulators or inhibitors of vessel growth may
need to be down-regulated. There are many naturally
occurring proteins that can inhibit angiogenesis, including
angiostatin, endostatin, interferon, platelet factor 4,
thorombospondin, prolactin 16 kd fragment, and tissue
inhibitor of metalloproteinase-1, -2, and -3 (Table 1).
Angiostatin is composed of one or more fragments of
plasminogen (Stack et al 1999). It induces apoptosis in
endothelial cells and tumor cells, and inhibits migration and
the formation of tubules in endothelial cells (Claesson-Welch
et al 1998; Lucas et al 1998). Immunohistochemical
examination of angiostatin-treated tumors indicated a
decrease in the expression of mRNA for VEGF and bFGF
(Kirsch et al 1998). Endostatin is a 20 kDa C-terminal
fragment of type XVIII collagen (O’Reilly et al 1997), a
component of the basement membrane. It binds to the α5β1/
αvβ3 integrin, the major fibronectin receptor in endothelial
cells (Rehn et al 2001; Wickstrom et al 2002) and may block
endothelial cell focal adhesions (Wickstrom et al 2002).
Table 1 Endogenous regulators of angiogenesis
Activators Inhibitors
 Growth factors
Vascular endothelial growth factor family
Acidic and basic fibroblast growth factor
Angiogenin
Angiostatin
Transforming growth factor
Tumor necrosis factor-α
Plated-delivered endothelial growth factor
Hepatocyte growth factor
Epidermal growth factor
Placental growth factor
Granulocyto colony stimulating factor
 Cytokines
Interleukin-1
Interleukin-6 Interleukin-10
Interleukin-8 Interleukin-12
 Proteases and protease inhibitors
Cathepsin Tissue inhibitor
metalloprotease
Gelatinase A, B Prasminogen
activator-inhibitor-1
Stromelysin
Urokinase-type plasminogen activator
 Trace elements
Copper Zinc
 Oncogenes
c-myc ras p53 Rb
c-src v-raf
c-jun
 Endogenous modulators
Alpha 5 Beta 3 integrin Angiopoietin-2
Angiopoitin-1 Angiotensin
Angiostatin II (AT1 receptor) Angiostatin II (AT2
receptor)
Endothelin Caveolin-1, -2
Erythropoietin Endostatin
Hypoxia Interferon-alpha
Nitric oxide synthase Isoflsvones
Plated-activating factor Platerat factor 4
Prostaglandin E
Prolactin (16 kd fragment)
Abbreviations:  AT1, angiotensin-1;  AT2, angiotensin-2.Vascular Health and Risk Management 2006:2(3) 216
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Endostatin also inhibits the growth factor (eg, bFGF and
VEGF-A), and induces proliferation and migration of
endothelial cells in vitro and in vivo (O’Reilly et al 1997;
Dhanabal et al 1999; Olsson et al 2004).
Angiogenesis and the prognosis of
cancer
Several studies have indicated that angiogenic activators
play an important part in the growth and spread of tumors.
On immunohistochemical examination, the VEGF family
and their receptors were found to be expressed in about
half of the human cancers investigated (Salven et al
1998). These factors are known to affect the prognosis
of adenocarcinomas that have developed in the uterine
cervix, (Hashimoto et al 2001), endometrium, (Hirai et
al 2001), ovary (Boocock et al 1995; Yokoyama et al
2003; Nishida et al 2004), and stomach (Yonemura et al
1999; Amioka et al 2002). In addition, a significant
correlation between the expression of VEGF and
prognosis has been described in colorectal cancer (Andre
et al 2000; George et al 2001; Furudoi et al 2002), breast
cancer (Kurebayashi et al 1999; Gunningham et al 2000;
Kinoshita et al 2001; Skobe et al 2001), lung cancer
(Decaussin et al 1999; Niki et al 2000; Kajita et al 2001),
head and neck squamous cell carcinoma (O-charoenrat
et al 2001), Kaposi sarcoma (Jussila et al 1998), and
malignant mesothelioma (Ohta et al 1999). These studies
also indicated that the levels of angiogenic factors in
tissue reflect the aggressiveness with which tumor cells
spread, and thus have predictive value in the identification
of the high-risk patients with poor prognosis.
Neovascularization reduces a tumor’s accessibility to
chemotherapeutic drugs. Increased interstitial pressure
from leaky vessels in the tumor, in the relative absence
of intratumoral lymphatic vessels, causes vascular
compression and central necrosis (Folkman 1995b). So
it is not surprising that the prognostic value of neoplastic
angiogenic factors is controversial. Work carried out in
our laboratory using immunohistochemistry to examine
the expression of the VEGF family and their receptors in
80 cases of ovarian carcinoma, revealed the presence of
VEGF-A, VEGF-C, VEGFR-2, and VEGFR-3 in the
cytoplasm of tumor cells, and also of endothelial cells of
the blood and lymph vessels in the stroma adjacent to
tumor nests (Nishida et al 2004). The tissue levels of
VEGF-C and VEGFR-2 significantly correlated with the
progression and prognosis of the cancer, while there was
no significant relationship between the expression of
VEGF-A and VEGFR-3 cancerous cell pathology
(Nishida et al 2004).
Antiangiogenic treatment of
cancer
For some localized solid malignant tumors, surgery has
curative potential, but the use of radiation and cytotoxic
chemotherapy is a more appropriate route of treatment for
surgically unresectable tumors (Kim et al 2002; Long 2003;
Brenner et al 2004; Pfister et al 2004; Lin and Beerm 2004;
Awada and de Castro 2005; Evans 2005; Goldberg 2005).
Despite advances in both therapeutic modalities, treatment
results are disappointing in patients with advanced disease
(Jemal et al 2005). A new therapeutic strategy is urgently
required.
Angiogenesis is regulated by both activator and inhibitor
molecules. The switch to the angiogenic phenotype involves
a change in the local equilibrium between positive and
negative regulators of angiogenesis. This signaling activates
certain genes in the host tissue that make proteins which
encourage the growth of blood vessels (Majima et al 2000;
Semenza 2002). Cancer cells require access to blood vessels
for growth and metastasis. The discovery of angiogenic
inhibitors provides hope for reducing the mortality and
morbidity from carcinomas. Five classes of angiogenic
antagonists are currently in clinical trials: inhibitors of
proteases (inhibit the synthesis of MMP); endothelial cell
migration and proliferation; angiogenic growth factors;
matrix proteins on the endothelial cell surface such as
integrins, copper; and inhibitors with unique mechanisms.
There has been a modest positive outcome with the use of
antiangiogenic drugs based on some clinical trials (Cobleigh
et al 2003; Yang et al 2003), but no long-term survival
benefits have been documented as yet (Mayer 2004).
However, when used in combination with chemotherapy or
radiation therapy, these drugs tend to increase survival
(Hurwiz et al 2004). Evidence seems to support the view
that cytotoxic agents and antiangiogenic agents would
destroy both cancer cells and endothelial cells (Teicher
1996). Cytotoxic therapy suppresses cancer directly and
angiogenic therapy suppresses it indirectly by depriving cells
of nutrients and oxygen (Rakesh 2005). The use of
angiogenesis-suppressors and receptor-inhibitors can
prohibit the neovascularization of cancer tissue as well as
growth of the tumor, and thus might be beneficial to the
treatment of cancer. Paradoxically, some studies have shown
that antiangiogenic agents as well as radiation can
compromise the delivery of drugs to tumors (Ma et al 2001).Vascular Health and Risk Management 2006:2(3) 217
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The new vasculature is structurally and functionally
abnormal (Jain 2004), and the blood vessels are immature
and leaky (Tong et al 2004). Unlike normal blood vessels:
1) tumor vessels have no or a detached pericyte and
basement membrane (Inai et al 2004; Tong et al 2004;
Winkler et al 2004); 2) the diameter of the vessel is smaller
(Yuan et al 1996; Izumi et al 2002; Tong et al 2004; Winkler
et al 2004); 3) the vascular density is heterogeneous (Izumi
et al 2002; Tong et al 2004; Winkler et al 2004); 4)
permeability to large molecules is high (Yuan et al 1996;
Tong et al 2004; Willett et al 2004; Winkler et al 2004); and
5) the pressure of microvascular and interstitial fluid is
almost the same (Lee et al 2000; Tong et al 2004; Willet et
al 2004). These abnormalities contribute to heterogeneity
in tumor blood flow. In addition, the pressure generated by
proliferating cancer cells compresses intratumoral blood and
lymphatic vessels and leads to an abnormal
microenvironment characterized by an impaired blood
supply, interstitial hypertension, hypoxia, and acidosis
(Padera et al 2004). It is possible that these factors
interfere with the delivery of therapeutic drugs, rendering
tumor cells resistant to both radiation and some forms of
cytotoxic therapy, induce genetic stability and select for
more malignant cells with increased metastatic potential,
and compromise the cytotoxic functions of immune cells.
Hence, Rakesh (2005) emphasizes that the tumor
vasculature should be normalized. Some trials based on
normalization of tumor vasculature have started,
however, data are not currently available. There is a report
that normalization can be achieved by controlling the dose
of an already existing medicine, for example, low-dose
anti-VEGF treatment. In the meantime, cancerous tissue
is composed of the neoplastic cells themselves and the
supporting stroma.
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